CD8A and neoplasm: Although combining anti-PD-L1 with DC–Pool Peptide vaccines failed to significantly influence (p > 0.05) the levels of polyfunctional CD8+ TILs recognizing either B16 or PVEC target cells, vaccines combined with either CKM or CKM + anti-PD-L1 antibody resulted in elevated frequencies of polyfunctional CD8+ TILs reactive against B16 tumor cells or PVECs (Figure 4A,B) but not EL4 tumor cells (Figure S4).